ArticleMolecular therapy. Nucleic acids2024
MicroRNA-centered theranostics for pulmoprotection in critical COVID-19.
Article in Molecular therapy. Nucleic acids, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Machine learning approaches for cancer prognosis and diagnosis via non-coding RNA: a comprehensive review.Briefings in bioinformatics · 2026Review
- Integration of the circulating miRNome and clinical information to predict 90-day mortality in elderly COVID-19 subphenotypes.iScience · 2026Article
- Host MiRNA responses during different waves of SARS-CoV-2: diagnostic implications of miR-19a-3p, miR-374b-5p, miR-15b-5p, and miR-320a-5p expression.BMC infectious diseases · 2026Article
- MicroRNA mapping of bronchial aspirate for molecular phenotyping and prognostication in patients on mechanical ventilation.Molecular therapy. Nucleic acids · 2025Article
- Minimalistic transcriptomic signatures permit accurate early prediction of COVID-19 mortality.JCI insight · 2025Article
- MicroRNAs, endometrial receptivity and molecular pathways.Reproductive biology and endocrinology : RB&E · 2024Review
- Machine learning for catalysing the integration of noncoding RNA in research and clinical practice.EBioMedicine · 2024Review
- Telomerase is essential for cardiac differentiation and sustained metabolism of human cardiomyocytes.Cellular and molecular life sciences : CMLS · 2024Article
- Exploring pulmoprotection in COVID-19: Moving toward microRNA-based theranostics.Molecular therapy. Nucleic acids · 2024Article
- Digital approaches in post-COVID healthcare: a systematic review of technological innovations in disease management.Biology methods & protocols · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elucidating the pathobiological mechanisms underlying post-acute pulmonary sequelae following SARS-CoV-2 infection is essential for early interventions and patient stratification. Here, we investigated the potential of microRNAs (miRNAs) as theranostic agents for pulmoprotection in critical illness survivors. Multicenter study including 172 ICU survivors. Diffusion impairment was defined as a lung-diffusing capacity for carbon monoxide (D
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.